697,614 AMERICAN DEPOSITARY SHARES EACH REPRESENTING 400 ORDINARY SHARES, NOMINAL VALUE £0.001 PER SHARE, PRE-FUNDED Warrants TO PURCHASE 1,911,176 AMERICAN DEPOSITARY SHARES, SERIES E Warrants TO PURCHASE 2,608,790 AMERICAN DEPOSITARY SHARES and...Underwriting Agreement • December 21st, 2023 • Biodexa Pharmaceuticals PLC • Pharmaceutical preparations • New York
The undersigned, Biodexa Pharmaceuticals Plc, a public limited company organized under the laws of England and Wales (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Biodexa Pharmaceuticals Plc, the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Ladenburg Thalmann & Co. Inc. is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein. The Underlying Ordinary Shares (as defined below) and War
LEAK-OUT AGREEMENTLeak-Out Agreement • December 21st, 2023 • Biodexa Pharmaceuticals PLC • Pharmaceutical preparations
This agreement (the “Leak-Out Agreement”) is being delivered to you in connection with an understanding by and between Biodexa Pharmaceuticals Plc., a public limited company organized under the laws of England and Wales (the “Company”), and the person or persons named on the signature pages hereto (collectively, the “Holder”).
